nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—CYP1A1—Clobetasol propionate—psoriasis	0.182	0.236	CbGbCtD
Toremifene—CYP1A1—Methoxsalen—psoriasis	0.0956	0.124	CbGbCtD
Toremifene—CYP1A2—Clobetasol propionate—psoriasis	0.0813	0.105	CbGbCtD
Toremifene—CYP1A1—Cholecalciferol—psoriasis	0.0633	0.0822	CbGbCtD
Toremifene—CYP1A2—Methoxsalen—psoriasis	0.0427	0.0554	CbGbCtD
Toremifene—CYP3A4—Calcitriol—psoriasis	0.0288	0.0373	CbGbCtD
Toremifene—CYP1A1—Dexamethasone—psoriasis	0.0274	0.0356	CbGbCtD
Toremifene—CYP3A4—Methoxsalen—psoriasis	0.0224	0.029	CbGbCtD
Toremifene—ABCB1—Mycophenolate mofetil—psoriasis	0.0215	0.0278	CbGbCtD
Toremifene—ABCB1—Betamethasone—psoriasis	0.0184	0.0239	CbGbCtD
Toremifene—ABCB1—Prednisolone—psoriasis	0.0182	0.0236	CbGbCtD
Toremifene—ABCB1—Hydrocortisone—psoriasis	0.0172	0.0223	CbGbCtD
Toremifene—ABCB1—Prednisone—psoriasis	0.0171	0.0222	CbGbCtD
Toremifene—ABCB1—Cyclosporine—psoriasis	0.0163	0.0211	CbGbCtD
Toremifene—CYP3A4—Cholecalciferol—psoriasis	0.0148	0.0192	CbGbCtD
Toremifene—CYP3A4—Mycophenolate mofetil—psoriasis	0.0129	0.0167	CbGbCtD
Toremifene—CYP3A4—Triamcinolone—psoriasis	0.0129	0.0167	CbGbCtD
Toremifene—CYP3A4—Betamethasone—psoriasis	0.011	0.0143	CbGbCtD
Toremifene—CYP3A4—Prednisolone—psoriasis	0.0109	0.0141	CbGbCtD
Toremifene—ABCB1—Dexamethasone—psoriasis	0.0107	0.0139	CbGbCtD
Toremifene—CYP3A4—Hydrocortisone—psoriasis	0.0103	0.0134	CbGbCtD
Toremifene—CYP3A4—Prednisone—psoriasis	0.0103	0.0133	CbGbCtD
Toremifene—CYP3A4—Cyclosporine—psoriasis	0.00974	0.0126	CbGbCtD
Toremifene—ABCB1—Methotrexate—psoriasis	0.0086	0.0112	CbGbCtD
Toremifene—CYP3A4—Dexamethasone—psoriasis	0.00641	0.00832	CbGbCtD
Toremifene—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.00112	0.0493	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IL22—psoriasis	0.000721	0.0316	CbGpPWpGaD
Toremifene—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000717	0.0314	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—IL23A—psoriasis	0.000637	0.0279	CbGpPWpGaD
Toremifene—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000553	0.0242	CbGpPWpGaD
Toremifene—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000467	0.0205	CbGpPWpGaD
Toremifene—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000461	0.0202	CbGpPWpGaD
Toremifene—ESR1—FOXM1 transcription factor network—TGFA—psoriasis	0.000458	0.0201	CbGpPWpGaD
Toremifene—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000379	0.0166	CbGpPWpGaD
Toremifene—ESR1—Estrogen Receptor Pathway—JUN—psoriasis	0.000346	0.0151	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000319	0.014	CbGpPWpGaD
Toremifene—ESR1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000299	0.0131	CbGpPWpGaD
Toremifene—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000298	0.0131	CbGpPWpGaD
Toremifene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000298	0.013	CbGpPWpGaD
Toremifene—ESR1—Nuclear Receptors—VDR—psoriasis	0.000296	0.013	CbGpPWpGaD
Toremifene—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000294	0.0129	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—REL—psoriasis	0.000292	0.0128	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000255	0.0112	CbGpPWpGaD
Toremifene—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000244	0.0107	CbGpPWpGaD
Toremifene—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000241	0.0106	CbGpPWpGaD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000236	0.0103	CbGpPWpGaD
Toremifene—ESR1—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000234	0.0103	CbGpPWpGaD
Toremifene—Myocardial infarction—Dexamethasone—psoriasis	0.000234	0.00113	CcSEcCtD
Toremifene—Neuropathy peripheral—Dexamethasone—psoriasis	0.000234	0.00113	CcSEcCtD
Toremifene—Neuropathy peripheral—Betamethasone—psoriasis	0.000234	0.00113	CcSEcCtD
Toremifene—Back pain—Mycophenolate mofetil—psoriasis	0.000232	0.00112	CcSEcCtD
Toremifene—Vision blurred—Cyclosporine—psoriasis	0.000231	0.00112	CcSEcCtD
Toremifene—Tremor—Cyclosporine—psoriasis	0.00023	0.00111	CcSEcCtD
Toremifene—Lethargy—Methotrexate—psoriasis	0.00023	0.00111	CcSEcCtD
Toremifene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00023	0.0101	CbGpPWpGaD
Toremifene—Arrhythmia—Prednisolone—psoriasis	0.000229	0.00111	CcSEcCtD
Toremifene—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000229	0.01	CbGpPWpGaD
Toremifene—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000227	0.00993	CbGpPWpGaD
Toremifene—Tremor—Mycophenolate mofetil—psoriasis	0.000224	0.00109	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000224	0.00982	CbGpPWpGaD
Toremifene—Insomnia—Mycophenolic acid—psoriasis	0.000224	0.00109	CcSEcCtD
Toremifene—Arrhythmia—Hydrocortisone—psoriasis	0.000224	0.00108	CcSEcCtD
Toremifene—Nausea—Acitretin—psoriasis	0.000224	0.00108	CcSEcCtD
Toremifene—Nausea—Fluocinolone Acetonide—psoriasis	0.000223	0.00108	CcSEcCtD
Toremifene—Dyspnoea—Mycophenolic acid—psoriasis	0.000221	0.00107	CcSEcCtD
Toremifene—Vertigo—Cyclosporine—psoriasis	0.000221	0.00107	CcSEcCtD
Toremifene—Leukopenia—Cyclosporine—psoriasis	0.00022	0.00106	CcSEcCtD
Toremifene—Mental disorder—Hydrocortisone—psoriasis	0.00022	0.00106	CcSEcCtD
Toremifene—ESR1—Estrogen signaling pathway—JUN—psoriasis	0.000219	0.00959	CbGpPWpGaD
Toremifene—Malnutrition—Hydrocortisone—psoriasis	0.000218	0.00106	CcSEcCtD
Toremifene—Decreased appetite—Mycophenolic acid—psoriasis	0.000215	0.00104	CcSEcCtD
Toremifene—Vertigo—Mycophenolate mofetil—psoriasis	0.000215	0.00104	CcSEcCtD
Toremifene—Leukopenia—Mycophenolate mofetil—psoriasis	0.000214	0.00104	CcSEcCtD
Toremifene—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000214	0.00104	CcSEcCtD
Toremifene—Fatigue—Mycophenolic acid—psoriasis	0.000213	0.00103	CcSEcCtD
Toremifene—Mood swings—Methotrexate—psoriasis	0.000213	0.00103	CcSEcCtD
Toremifene—Asthenia—Hydroxyurea—psoriasis	0.000212	0.00103	CcSEcCtD
Toremifene—Weight increased—Prednisone—psoriasis	0.000212	0.00103	CcSEcCtD
Toremifene—Ataxia—Methotrexate—psoriasis	0.000212	0.00103	CcSEcCtD
Toremifene—Pain—Mycophenolic acid—psoriasis	0.000212	0.00103	CcSEcCtD
Toremifene—Constipation—Mycophenolic acid—psoriasis	0.000212	0.00103	CcSEcCtD
Toremifene—Arrhythmia—Triamcinolone—psoriasis	0.000211	0.00102	CcSEcCtD
Toremifene—ESR1—Estrogen signaling pathway—NFKB1—psoriasis	0.000211	0.00923	CbGpPWpGaD
Toremifene—Vision blurred—Prednisolone—psoriasis	0.00021	0.00102	CcSEcCtD
Toremifene—Chest pain—Cyclosporine—psoriasis	0.000209	0.00101	CcSEcCtD
Toremifene—Liver function test abnormal—Methotrexate—psoriasis	0.000208	0.00101	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000208	0.00101	CcSEcCtD
Toremifene—ESR1—Nuclear Receptors—PPARG—psoriasis	0.000207	0.00905	CbGpPWpGaD
Toremifene—Visual impairment—Dexamethasone—psoriasis	0.000206	0.001	CcSEcCtD
Toremifene—Visual impairment—Betamethasone—psoriasis	0.000206	0.001	CcSEcCtD
Toremifene—Acute coronary syndrome—Prednisone—psoriasis	0.000205	0.000992	CcSEcCtD
Toremifene—Chest pain—Mycophenolate mofetil—psoriasis	0.000204	0.000988	CcSEcCtD
Toremifene—Neuropathy peripheral—Prednisone—psoriasis	0.000204	0.000987	CcSEcCtD
Toremifene—Myocardial infarction—Prednisone—psoriasis	0.000204	0.000987	CcSEcCtD
Toremifene—Breast disorder—Methotrexate—psoriasis	0.000204	0.000986	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000202	0.000981	CcSEcCtD
Toremifene—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000201	0.00881	CbGpPWpGaD
Toremifene—Vertigo—Prednisolone—psoriasis	0.000201	0.000973	CcSEcCtD
Toremifene—Oedema—Cyclosporine—psoriasis	0.0002	0.000971	CcSEcCtD
Toremifene—Eye disorder—Betamethasone—psoriasis	0.0002	0.00097	CcSEcCtD
Toremifene—Eye disorder—Dexamethasone—psoriasis	0.0002	0.00097	CcSEcCtD
Toremifene—Back pain—Triamcinolone—psoriasis	0.000199	0.000963	CcSEcCtD
Toremifene—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000198	0.00869	CbGpPWpGaD
Toremifene—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000198	0.00867	CbGpPWpGaD
Toremifene—Nervous system disorder—Cyclosporine—psoriasis	0.000196	0.000952	CcSEcCtD
Toremifene—Thrombocytopenia—Cyclosporine—psoriasis	0.000196	0.000951	CcSEcCtD
Toremifene—Vertigo—Hydrocortisone—psoriasis	0.000196	0.00095	CcSEcCtD
Toremifene—Dizziness—Hydroxyurea—psoriasis	0.000195	0.000947	CcSEcCtD
Toremifene—Oedema—Mycophenolate mofetil—psoriasis	0.000195	0.000947	CcSEcCtD
Toremifene—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000195	0.00854	CbGpPWpGaD
Toremifene—Skin disorder—Cyclosporine—psoriasis	0.000195	0.000943	CcSEcCtD
Toremifene—Angiopathy—Dexamethasone—psoriasis	0.000194	0.000941	CcSEcCtD
Toremifene—Angiopathy—Betamethasone—psoriasis	0.000194	0.000941	CcSEcCtD
Toremifene—Hyperhidrosis—Cyclosporine—psoriasis	0.000194	0.000939	CcSEcCtD
Toremifene—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000192	0.000929	CcSEcCtD
Toremifene—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000191	0.000927	CcSEcCtD
Toremifene—Arrhythmia—Dexamethasone—psoriasis	0.000191	0.000927	CcSEcCtD
Toremifene—Arrhythmia—Betamethasone—psoriasis	0.000191	0.000927	CcSEcCtD
Toremifene—Anorexia—Cyclosporine—psoriasis	0.000191	0.000925	CcSEcCtD
Toremifene—Skin disorder—Mycophenolate mofetil—psoriasis	0.00019	0.00092	CcSEcCtD
Toremifene—Alopecia—Betamethasone—psoriasis	0.000189	0.000917	CcSEcCtD
Toremifene—Alopecia—Dexamethasone—psoriasis	0.000189	0.000917	CcSEcCtD
Toremifene—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000189	0.000916	CcSEcCtD
Toremifene—Vomiting—Hydroxyurea—psoriasis	0.000188	0.000911	CcSEcCtD
Toremifene—Rash—Hydroxyurea—psoriasis	0.000186	0.000903	CcSEcCtD
Toremifene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000186	0.00816	CbGpPWpGaD
Toremifene—Anorexia—Mycophenolate mofetil—psoriasis	0.000186	0.000903	CcSEcCtD
Toremifene—Dermatitis—Hydroxyurea—psoriasis	0.000186	0.000903	CcSEcCtD
Toremifene—Headache—Hydroxyurea—psoriasis	0.000185	0.000898	CcSEcCtD
Toremifene—Vertigo—Triamcinolone—psoriasis	0.000185	0.000894	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000184	0.000894	CcSEcCtD
Toremifene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000184	0.00805	CbGpPWpGaD
Toremifene—Oedema—Prednisolone—psoriasis	0.000182	0.000883	CcSEcCtD
Toremifene—Insomnia—Cyclosporine—psoriasis	0.000181	0.000878	CcSEcCtD
Toremifene—Dyspnoea—Cyclosporine—psoriasis	0.000179	0.000866	CcSEcCtD
Toremifene—Oedema—Hydrocortisone—psoriasis	0.000178	0.000863	CcSEcCtD
Toremifene—Asthenia—Mycophenolic acid—psoriasis	0.000178	0.000861	CcSEcCtD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000177	0.00777	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000177	0.00775	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—IL10—psoriasis	0.000177	0.00774	CbGpPWpGaD
Toremifene—Insomnia—Mycophenolate mofetil—psoriasis	0.000177	0.000857	CcSEcCtD
Toremifene—Hyperhidrosis—Prednisolone—psoriasis	0.000176	0.000854	CcSEcCtD
Toremifene—Nausea—Hydroxyurea—psoriasis	0.000176	0.000851	CcSEcCtD
Toremifene—Pruritus—Mycophenolic acid—psoriasis	0.000175	0.000849	CcSEcCtD
Toremifene—Nervous system disorder—Hydrocortisone—psoriasis	0.000175	0.000846	CcSEcCtD
Toremifene—Eye disorder—Prednisone—psoriasis	0.000174	0.000844	CcSEcCtD
Toremifene—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000174	0.000844	CcSEcCtD
Toremifene—Decreased appetite—Cyclosporine—psoriasis	0.000174	0.000844	CcSEcCtD
Toremifene—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000174	0.0076	CbGpPWpGaD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000173	0.00759	CbGpPWpGaD
Toremifene—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000173	0.000838	CcSEcCtD
Toremifene—Skin disorder—Hydrocortisone—psoriasis	0.000173	0.000838	CcSEcCtD
Toremifene—Fatigue—Cyclosporine—psoriasis	0.000173	0.000837	CcSEcCtD
Toremifene—Hyperhidrosis—Hydrocortisone—psoriasis	0.000172	0.000834	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—IL4—psoriasis	0.000172	0.00753	CbGpPWpGaD
Toremifene—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000171	0.00751	CbGpPWpGaD
Toremifene—Constipation—Cyclosporine—psoriasis	0.000171	0.00083	CcSEcCtD
Toremifene—Pain—Cyclosporine—psoriasis	0.000171	0.00083	CcSEcCtD
Toremifene—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00017	0.000823	CcSEcCtD
Toremifene—Anorexia—Hydrocortisone—psoriasis	0.00017	0.000822	CcSEcCtD
Toremifene—Angiopathy—Prednisone—psoriasis	0.000169	0.00082	CcSEcCtD
Toremifene—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000169	0.000818	CcSEcCtD
Toremifene—Oedema—Triamcinolone—psoriasis	0.000168	0.000812	CcSEcCtD
Toremifene—Vertigo—Betamethasone—psoriasis	0.000167	0.000811	CcSEcCtD
Toremifene—Vertigo—Dexamethasone—psoriasis	0.000167	0.000811	CcSEcCtD
Toremifene—Constipation—Mycophenolate mofetil—psoriasis	0.000167	0.00081	CcSEcCtD
Toremifene—Pain—Mycophenolate mofetil—psoriasis	0.000167	0.00081	CcSEcCtD
Toremifene—Arrhythmia—Prednisone—psoriasis	0.000167	0.000807	CcSEcCtD
Toremifene—Sweating—Methotrexate—psoriasis	0.000166	0.000806	CcSEcCtD
Toremifene—Insomnia—Prednisolone—psoriasis	0.000165	0.000799	CcSEcCtD
Toremifene—Alopecia—Prednisone—psoriasis	0.000165	0.000798	CcSEcCtD
Toremifene—Hepatobiliary disease—Methotrexate—psoriasis	0.000164	0.000796	CcSEcCtD
Toremifene—Dizziness—Mycophenolic acid—psoriasis	0.000164	0.000794	CcSEcCtD
Toremifene—Mental disorder—Prednisone—psoriasis	0.000163	0.000792	CcSEcCtD
Toremifene—ESR1—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000163	0.00715	CbGpPWpGaD
Toremifene—Malnutrition—Prednisone—psoriasis	0.000162	0.000787	CcSEcCtD
Toremifene—Hyperhidrosis—Triamcinolone—psoriasis	0.000162	0.000785	CcSEcCtD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000162	0.00708	CbGpPWpGaD
Toremifene—Insomnia—Hydrocortisone—psoriasis	0.000161	0.00078	CcSEcCtD
Toremifene—Vomiting—Mycophenolic acid—psoriasis	0.000157	0.000763	CcSEcCtD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000157	0.00689	CbGpPWpGaD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000156	0.00685	CbGpPWpGaD
Toremifene—Rash—Mycophenolic acid—psoriasis	0.000156	0.000757	CcSEcCtD
Toremifene—Dermatitis—Mycophenolic acid—psoriasis	0.000156	0.000756	CcSEcCtD
Toremifene—Pain—Prednisolone—psoriasis	0.000156	0.000755	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—HLA-A—psoriasis	0.000156	0.00682	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—NOS2—psoriasis	0.000155	0.00681	CbGpPWpGaD
Toremifene—Headache—Mycophenolic acid—psoriasis	0.000155	0.000752	CcSEcCtD
Toremifene—Decreased appetite—Hydrocortisone—psoriasis	0.000155	0.00075	CcSEcCtD
Toremifene—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000154	0.000745	CcSEcCtD
Toremifene—Fatigue—Hydrocortisone—psoriasis	0.000153	0.000744	CcSEcCtD
Toremifene—Vision blurred—Prednisone—psoriasis	0.000153	0.000741	CcSEcCtD
Toremifene—Pain—Hydrocortisone—psoriasis	0.000152	0.000738	CcSEcCtD
Toremifene—Oedema—Betamethasone—psoriasis	0.000152	0.000737	CcSEcCtD
Toremifene—Oedema—Dexamethasone—psoriasis	0.000152	0.000737	CcSEcCtD
Toremifene—Insomnia—Triamcinolone—psoriasis	0.000152	0.000735	CcSEcCtD
Toremifene—Visual impairment—Methotrexate—psoriasis	0.00015	0.000728	CcSEcCtD
Toremifene—Dyspnoea—Triamcinolone—psoriasis	0.000149	0.000724	CcSEcCtD
Toremifene—Nervous system disorder—Dexamethasone—psoriasis	0.000149	0.000723	CcSEcCtD
Toremifene—Nervous system disorder—Betamethasone—psoriasis	0.000149	0.000723	CcSEcCtD
Toremifene—Thrombocytopenia—Dexamethasone—psoriasis	0.000149	0.000722	CcSEcCtD
Toremifene—Thrombocytopenia—Betamethasone—psoriasis	0.000149	0.000722	CcSEcCtD
Toremifene—Nausea—Mycophenolic acid—psoriasis	0.000147	0.000713	CcSEcCtD
Toremifene—Hyperhidrosis—Dexamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Toremifene—Hyperhidrosis—Betamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Toremifene—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000146	0.00639	CbGpPWpGaD
Toremifene—Vertigo—Prednisone—psoriasis	0.000146	0.000707	CcSEcCtD
Toremifene—Eye disorder—Methotrexate—psoriasis	0.000146	0.000706	CcSEcCtD
Toremifene—Anorexia—Dexamethasone—psoriasis	0.000145	0.000703	CcSEcCtD
Toremifene—Anorexia—Betamethasone—psoriasis	0.000145	0.000703	CcSEcCtD
Toremifene—Fatigue—Triamcinolone—psoriasis	0.000145	0.0007	CcSEcCtD
Toremifene—Asthenia—Cyclosporine—psoriasis	0.000144	0.000697	CcSEcCtD
Toremifene—Pain—Triamcinolone—psoriasis	0.000143	0.000695	CcSEcCtD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000143	0.00626	CbGpPWpGaD
Toremifene—Pruritus—Cyclosporine—psoriasis	0.000142	0.000687	CcSEcCtD
Toremifene—Angiopathy—Methotrexate—psoriasis	0.000141	0.000685	CcSEcCtD
Toremifene—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.00014	0.00615	CbGpPWpGaD
Toremifene—Mediastinal disorder—Methotrexate—psoriasis	0.00014	0.000681	CcSEcCtD
Toremifene—Asthenia—Mycophenolate mofetil—psoriasis	0.00014	0.000679	CcSEcCtD
Toremifene—Chills—Methotrexate—psoriasis	0.00014	0.000678	CcSEcCtD
Toremifene—Pruritus—Mycophenolate mofetil—psoriasis	0.000138	0.00067	CcSEcCtD
Toremifene—Alopecia—Methotrexate—psoriasis	0.000138	0.000667	CcSEcCtD
Toremifene—ESR1—Leptin signaling pathway—LEP—psoriasis	0.000138	0.00603	CbGpPWpGaD
Toremifene—Insomnia—Dexamethasone—psoriasis	0.000138	0.000667	CcSEcCtD
Toremifene—Insomnia—Betamethasone—psoriasis	0.000138	0.000667	CcSEcCtD
Toremifene—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000137	0.00602	CbGpPWpGaD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000137	0.000665	CcSEcCtD
Toremifene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000137	0.00599	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000137	0.00598	CbGpPWpGaD
Toremifene—Mental disorder—Methotrexate—psoriasis	0.000137	0.000662	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—IL13—psoriasis	0.000136	0.00595	CbGpPWpGaD
Toremifene—Malnutrition—Methotrexate—psoriasis	0.000136	0.000657	CcSEcCtD
Toremifene—Dizziness—Cyclosporine—psoriasis	0.000132	0.000642	CcSEcCtD
Toremifene—Oedema—Prednisone—psoriasis	0.000132	0.000642	CcSEcCtD
Toremifene—Decreased appetite—Betamethasone—psoriasis	0.000132	0.000641	CcSEcCtD
Toremifene—Decreased appetite—Dexamethasone—psoriasis	0.000132	0.000641	CcSEcCtD
Toremifene—Gastrointestinal disorder—Betamethasone—psoriasis	0.000131	0.000636	CcSEcCtD
Toremifene—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000131	0.000636	CcSEcCtD
Toremifene—Back pain—Methotrexate—psoriasis	0.000131	0.000636	CcSEcCtD
Toremifene—Fatigue—Betamethasone—psoriasis	0.000131	0.000636	CcSEcCtD
Toremifene—Fatigue—Dexamethasone—psoriasis	0.000131	0.000636	CcSEcCtD
Toremifene—ESR1—FOXA1 transcription factor network—JUN—psoriasis	0.00013	0.00571	CbGpPWpGaD
Toremifene—Pain—Betamethasone—psoriasis	0.00013	0.00063	CcSEcCtD
Toremifene—Pain—Dexamethasone—psoriasis	0.00013	0.00063	CcSEcCtD
Toremifene—Nervous system disorder—Prednisone—psoriasis	0.00013	0.00063	CcSEcCtD
Toremifene—Dizziness—Mycophenolate mofetil—psoriasis	0.000129	0.000626	CcSEcCtD
Toremifene—Skin disorder—Prednisone—psoriasis	0.000129	0.000624	CcSEcCtD
Toremifene—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000128	0.00562	CbGpPWpGaD
Toremifene—Hyperhidrosis—Prednisone—psoriasis	0.000128	0.000621	CcSEcCtD
Toremifene—Vision blurred—Methotrexate—psoriasis	0.000128	0.00062	CcSEcCtD
Toremifene—Asthenia—Hydrocortisone—psoriasis	0.000128	0.000619	CcSEcCtD
Toremifene—Vomiting—Cyclosporine—psoriasis	0.000127	0.000617	CcSEcCtD
Toremifene—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000126	0.00554	CbGpPWpGaD
Toremifene—Rash—Cyclosporine—psoriasis	0.000126	0.000612	CcSEcCtD
Toremifene—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000126	0.00553	CbGpPWpGaD
Toremifene—Anorexia—Prednisone—psoriasis	0.000126	0.000612	CcSEcCtD
Toremifene—Dermatitis—Cyclosporine—psoriasis	0.000126	0.000612	CcSEcCtD
Toremifene—Pruritus—Hydrocortisone—psoriasis	0.000126	0.00061	CcSEcCtD
Toremifene—Headache—Cyclosporine—psoriasis	0.000125	0.000608	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000125	0.00547	CbGpPWpGaD
Toremifene—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000124	0.00545	CbGpPWpGaD
Toremifene—Vomiting—Mycophenolate mofetil—psoriasis	0.000124	0.000602	CcSEcCtD
Toremifene—Rash—Mycophenolate mofetil—psoriasis	0.000123	0.000597	CcSEcCtD
Toremifene—Dermatitis—Mycophenolate mofetil—psoriasis	0.000123	0.000597	CcSEcCtD
Toremifene—Headache—Mycophenolate mofetil—psoriasis	0.000122	0.000593	CcSEcCtD
Toremifene—Vertigo—Methotrexate—psoriasis	0.000122	0.000591	CcSEcCtD
Toremifene—Leukopenia—Methotrexate—psoriasis	0.000121	0.000588	CcSEcCtD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000121	0.0053	CbGpPWpGaD
Toremifene—Dizziness—Prednisolone—psoriasis	0.000121	0.000584	CcSEcCtD
Toremifene—Asthenia—Triamcinolone—psoriasis	0.00012	0.000583	CcSEcCtD
Toremifene—Insomnia—Prednisone—psoriasis	0.00012	0.000581	CcSEcCtD
Toremifene—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000119	0.00523	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—IFNG—psoriasis	0.000119	0.00522	CbGpPWpGaD
Toremifene—Nausea—Cyclosporine—psoriasis	0.000119	0.000577	CcSEcCtD
Toremifene—Pruritus—Triamcinolone—psoriasis	0.000119	0.000575	CcSEcCtD
Toremifene—Dizziness—Hydrocortisone—psoriasis	0.000118	0.000571	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000116	0.00509	CbGpPWpGaD
Toremifene—Nausea—Mycophenolate mofetil—psoriasis	0.000116	0.000563	CcSEcCtD
Toremifene—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000116	0.00508	CbGpPWpGaD
Toremifene—Chest pain—Methotrexate—psoriasis	0.000115	0.00056	CcSEcCtD
Toremifene—Decreased appetite—Prednisone—psoriasis	0.000115	0.000558	CcSEcCtD
Toremifene—Rash—Prednisolone—psoriasis	0.000115	0.000557	CcSEcCtD
Toremifene—Dermatitis—Prednisolone—psoriasis	0.000115	0.000557	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000115	0.000556	CcSEcCtD
Toremifene—Fatigue—Prednisone—psoriasis	0.000114	0.000553	CcSEcCtD
Toremifene—Headache—Prednisolone—psoriasis	0.000114	0.000553	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000113	0.00496	CbGpPWpGaD
Toremifene—Constipation—Prednisone—psoriasis	0.000113	0.000549	CcSEcCtD
Toremifene—Vomiting—Hydrocortisone—psoriasis	0.000113	0.000549	CcSEcCtD
Toremifene—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000113	0.00494	CbGpPWpGaD
Toremifene—Rash—Hydrocortisone—psoriasis	0.000112	0.000544	CcSEcCtD
Toremifene—Dermatitis—Hydrocortisone—psoriasis	0.000112	0.000544	CcSEcCtD
Toremifene—Headache—Hydrocortisone—psoriasis	0.000112	0.000541	CcSEcCtD
Toremifene—Dizziness—Triamcinolone—psoriasis	0.000111	0.000537	CcSEcCtD
Toremifene—ESR1—ATF-2 transcription factor network—CXCL8—psoriasis	0.000111	0.00485	CbGpPWpGaD
Toremifene—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000111	0.00485	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.00011	0.00481	CbGpPWpGaD
Toremifene—Asthenia—Dexamethasone—psoriasis	0.000109	0.000529	CcSEcCtD
Toremifene—Asthenia—Betamethasone—psoriasis	0.000109	0.000529	CcSEcCtD
Toremifene—Nervous system disorder—Methotrexate—psoriasis	0.000109	0.000526	CcSEcCtD
Toremifene—Thrombocytopenia—Methotrexate—psoriasis	0.000108	0.000525	CcSEcCtD
Toremifene—Nausea—Prednisolone—psoriasis	0.000108	0.000525	CcSEcCtD
Toremifene—Pruritus—Dexamethasone—psoriasis	0.000108	0.000522	CcSEcCtD
Toremifene—Pruritus—Betamethasone—psoriasis	0.000108	0.000522	CcSEcCtD
Toremifene—Skin disorder—Methotrexate—psoriasis	0.000108	0.000521	CcSEcCtD
Toremifene—Hyperhidrosis—Methotrexate—psoriasis	0.000107	0.000519	CcSEcCtD
Toremifene—Vomiting—Triamcinolone—psoriasis	0.000107	0.000517	CcSEcCtD
Toremifene—ESR1—Regulation of Telomerase—IFNG—psoriasis	0.000106	0.00466	CbGpPWpGaD
Toremifene—Nausea—Hydrocortisone—psoriasis	0.000106	0.000512	CcSEcCtD
Toremifene—Rash—Triamcinolone—psoriasis	0.000106	0.000512	CcSEcCtD
Toremifene—Dermatitis—Triamcinolone—psoriasis	0.000106	0.000512	CcSEcCtD
Toremifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000106	0.00462	CbGpPWpGaD
Toremifene—Anorexia—Methotrexate—psoriasis	0.000106	0.000511	CcSEcCtD
Toremifene—Headache—Triamcinolone—psoriasis	0.000105	0.000509	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—IFNG—psoriasis	0.000104	0.00455	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—TARS—psoriasis	0.000104	0.00454	CbGpPWpGaD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000103	0.00452	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—JUN—psoriasis	0.000103	0.00451	CbGpPWpGaD
Toremifene—Dizziness—Betamethasone—psoriasis	0.000101	0.000487	CcSEcCtD
Toremifene—Dizziness—Dexamethasone—psoriasis	0.000101	0.000487	CcSEcCtD
Toremifene—Insomnia—Methotrexate—psoriasis	0.0001	0.000485	CcSEcCtD
Toremifene—Nausea—Triamcinolone—psoriasis	9.96e-05	0.000483	CcSEcCtD
Toremifene—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.9e-05	0.00434	CbGpPWpGaD
Toremifene—Dyspnoea—Methotrexate—psoriasis	9.87e-05	0.000478	CcSEcCtD
Toremifene—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.76e-05	0.00428	CbGpPWpGaD
Toremifene—Vomiting—Betamethasone—psoriasis	9.67e-05	0.000469	CcSEcCtD
Toremifene—Vomiting—Dexamethasone—psoriasis	9.67e-05	0.000469	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—CXCL8—psoriasis	9.67e-05	0.00423	CbGpPWpGaD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	9.65e-05	0.00423	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	9.64e-05	0.00422	CbGpPWpGaD
Toremifene—Decreased appetite—Methotrexate—psoriasis	9.62e-05	0.000466	CcSEcCtD
Toremifene—Rash—Betamethasone—psoriasis	9.59e-05	0.000465	CcSEcCtD
Toremifene—Rash—Dexamethasone—psoriasis	9.59e-05	0.000465	CcSEcCtD
Toremifene—Dermatitis—Betamethasone—psoriasis	9.58e-05	0.000464	CcSEcCtD
Toremifene—Dermatitis—Dexamethasone—psoriasis	9.58e-05	0.000464	CcSEcCtD
Toremifene—Gastrointestinal disorder—Methotrexate—psoriasis	9.56e-05	0.000463	CcSEcCtD
Toremifene—Fatigue—Methotrexate—psoriasis	9.54e-05	0.000463	CcSEcCtD
Toremifene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.54e-05	0.00418	CbGpPWpGaD
Toremifene—Headache—Betamethasone—psoriasis	9.53e-05	0.000462	CcSEcCtD
Toremifene—Headache—Dexamethasone—psoriasis	9.53e-05	0.000462	CcSEcCtD
Toremifene—Asthenia—Prednisone—psoriasis	9.5e-05	0.000461	CcSEcCtD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	9.47e-05	0.00415	CbGpPWpGaD
Toremifene—Pain—Methotrexate—psoriasis	9.47e-05	0.000459	CcSEcCtD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—TNF—psoriasis	9.41e-05	0.00412	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.38e-05	0.00411	CbGpPWpGaD
Toremifene—Pruritus—Prednisone—psoriasis	9.37e-05	0.000454	CcSEcCtD
Toremifene—ESR1—Regulation of Telomerase—JUN—psoriasis	9.2e-05	0.00403	CbGpPWpGaD
Toremifene—Nausea—Dexamethasone—psoriasis	9.03e-05	0.000438	CcSEcCtD
Toremifene—Nausea—Betamethasone—psoriasis	9.03e-05	0.000438	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—JUN—psoriasis	8.99e-05	0.00394	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—NFKB1—psoriasis	8.85e-05	0.00388	CbGpPWpGaD
Toremifene—ESR1—LKB1 signaling events—TP53—psoriasis	8.76e-05	0.00384	CbGpPWpGaD
Toremifene—Dizziness—Prednisone—psoriasis	8.76e-05	0.000425	CcSEcCtD
Toremifene—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.54e-05	0.00374	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IL10—psoriasis	8.49e-05	0.00372	CbGpPWpGaD
Toremifene—Vomiting—Prednisone—psoriasis	8.42e-05	0.000408	CcSEcCtD
Toremifene—Rash—Prednisone—psoriasis	8.35e-05	0.000405	CcSEcCtD
Toremifene—Dermatitis—Prednisone—psoriasis	8.34e-05	0.000404	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	8.33e-05	0.00365	CbGpPWpGaD
Toremifene—Headache—Prednisone—psoriasis	8.3e-05	0.000402	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—IL4—psoriasis	8.26e-05	0.00362	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—NFKB1—psoriasis	8.19e-05	0.00359	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—HLA-B—psoriasis	8.08e-05	0.00354	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	8.07e-05	0.00353	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	8.02e-05	0.00351	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	8e-05	0.0035	CbGpPWpGaD
Toremifene—Asthenia—Methotrexate—psoriasis	7.94e-05	0.000385	CcSEcCtD
Toremifene—Nausea—Prednisone—psoriasis	7.87e-05	0.000381	CcSEcCtD
Toremifene—Pruritus—Methotrexate—psoriasis	7.83e-05	0.00038	CcSEcCtD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.52e-05	0.00329	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.48e-05	0.00328	CbGpPWpGaD
Toremifene—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.39e-05	0.00324	CbGpPWpGaD
Toremifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.36e-05	0.00322	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—STAT3—psoriasis	7.36e-05	0.00322	CbGpPWpGaD
Toremifene—Dizziness—Methotrexate—psoriasis	7.32e-05	0.000355	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	7.28e-05	0.00319	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.23e-05	0.00317	CbGpPWpGaD
Toremifene—Vomiting—Methotrexate—psoriasis	7.04e-05	0.000341	CcSEcCtD
Toremifene—Rash—Methotrexate—psoriasis	6.98e-05	0.000338	CcSEcCtD
Toremifene—Dermatitis—Methotrexate—psoriasis	6.97e-05	0.000338	CcSEcCtD
Toremifene—Headache—Methotrexate—psoriasis	6.93e-05	0.000336	CcSEcCtD
Toremifene—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.84e-05	0.00299	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—CARM1—psoriasis	6.77e-05	0.00297	CbGpPWpGaD
Toremifene—Nausea—Methotrexate—psoriasis	6.58e-05	0.000319	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.24e-05	0.00273	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.24e-05	0.00273	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—IL6—psoriasis	6.23e-05	0.00273	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.14e-05	0.00269	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.07e-05	0.00266	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—TYK2—psoriasis	5.97e-05	0.00262	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—TP53—psoriasis	5.93e-05	0.0026	CbGpPWpGaD
Toremifene—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.85e-05	0.00256	CbGpPWpGaD
Toremifene—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.72e-05	0.00251	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—IL6—psoriasis	5.43e-05	0.00238	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.31e-05	0.00233	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.11e-05	0.00224	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IFNG—psoriasis	4.99e-05	0.00219	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.98e-05	0.00218	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	4.86e-05	0.00213	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HCAR2—psoriasis	4.8e-05	0.0021	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.68e-05	0.00205	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.64e-05	0.00203	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.64e-05	0.00203	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.35e-05	0.00191	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.24e-05	0.00186	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TAGAP—psoriasis	4.16e-05	0.00182	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NDUFA5—psoriasis	4.05e-05	0.00177	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—VDR—psoriasis	4.04e-05	0.00177	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.03e-05	0.00176	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.98e-05	0.00174	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.98e-05	0.00174	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.94e-05	0.00173	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.88e-05	0.0017	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.82e-05	0.00167	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.77e-05	0.00165	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.77e-05	0.00165	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.52e-05	0.00154	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYP2S1—psoriasis	3.44e-05	0.00151	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—CARM1—psoriasis	3.26e-05	0.00143	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—TNF—psoriasis	3.23e-05	0.00142	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NDUFA5—psoriasis	3.23e-05	0.00142	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.21e-05	0.00141	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	3.21e-05	0.0014	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.01e-05	0.00132	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3e-05	0.00132	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—IL6—psoriasis	2.92e-05	0.00128	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.86e-05	0.00125	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—PPARG—psoriasis	2.82e-05	0.00123	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYP2S1—psoriasis	2.75e-05	0.0012	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.66e-05	0.00116	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NDUFA5—psoriasis	2.58e-05	0.00113	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CCL20—psoriasis	2.49e-05	0.00109	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.4e-05	0.00105	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYP2S1—psoriasis	2.19e-05	0.000961	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.13e-05	0.000933	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.05e-05	0.000898	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NDUFA5—psoriasis	1.99e-05	0.000872	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—VDR—psoriasis	1.95e-05	0.000853	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.86e-05	0.000815	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.8e-05	0.00079	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYP2S1—psoriasis	1.69e-05	0.000741	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CARM1—psoriasis	1.68e-05	0.000736	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.59e-05	0.000699	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.57e-05	0.000688	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.41e-05	0.000616	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000601	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PPARG—psoriasis	1.36e-05	0.000595	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CARM1—psoriasis	1.34e-05	0.000588	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.15e-05	0.000503	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CARM1—psoriasis	1.07e-05	0.000469	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CAT—psoriasis	1.03e-05	0.000453	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000444	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000444	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1e-05	0.000438	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NFKBIA—psoriasis	9.44e-06	0.000414	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CARM1—psoriasis	8.27e-06	0.000362	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CAT—psoriasis	8.25e-06	0.000361	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—APOE—psoriasis	8.03e-06	0.000352	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TYK2—psoriasis	7.73e-06	0.000339	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PPARG—psoriasis	6.99e-06	0.000306	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CXCL8—psoriasis	6.73e-06	0.000295	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CAT—psoriasis	6.59e-06	0.000289	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—APOE—psoriasis	6.41e-06	0.000281	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—JUN—psoriasis	6.26e-06	0.000274	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NFKB1—psoriasis	6.03e-06	0.000264	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PPARG—psoriasis	5.58e-06	0.000245	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—VEGFA—psoriasis	5.47e-06	0.00024	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—STAT3—psoriasis	5.42e-06	0.000237	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—APOE—psoriasis	5.12e-06	0.000224	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CAT—psoriasis	5.08e-06	0.000223	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PPARG—psoriasis	4.46e-06	0.000195	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TP53—psoriasis	4.13e-06	0.000181	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—APOE—psoriasis	3.95e-06	0.000173	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL6—psoriasis	3.78e-06	0.000166	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PPARG—psoriasis	3.44e-06	0.000151	CbGpPWpGaD
